EUVIMEDEUVIMED entdecken
Crossref

Revealing 5-(3,5-difluorobenzyl)-1H-indazole as the active pharmacophore of ALK/ROS1 dual inhibitors through theoretical calculations and biological activity evaluations

Xiaoling Huang, Shidi Xu, Yufeng An, Xinya Lv, Lulu Tian, Shan Xu, Linxiao Wang, Wufu Zhu

Bioorganic Chemistry · 2025

DOI: 10.1016/j.bioorg.2024.108014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Xiaoling Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road…. Hauptthemen laut MEDLINE: Indazoles, Protein Kinase Inhibitors, Anaplastic Lymphoma Kinase, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic lymphoma kinase (ALK) and tyrosine protein kinase (ROS1) are recognized as driver genes in lung cancer, with dual inhibition of both targets offering a promising approach to enhance therapeutic outcomes in non-small cell lung cancer (NSCLC). Although numerous ALK/ROS1 inhibitors have received FDA approval, detailed research into the essential active structural motifs within these inhibitors remains limited. Addressing this gap, the current study employed computer-aided drug design (CADD) methodologies, incorporating bioisosteric and conformational similarity principles to design and synthesize 31 dual-target 2-morpholinobenzamide derivatives. These derivatives each include the 5-(3,5-difluorobenzyl)-1H-indazole, 4-benzylmorpholine, and thiophene moieties. Based on docking binding energies, we proposed that 5-(3,5-difluorobenzyl)-1H-indazole may represent a key pharmacophore for ALK/ROS1 activity. Subsequent kinase and cellular assays validated this hypothesis, with compound X4 exhibiting optimal inhibitory activity against both ALK and ROS1 kinases and lung cancer cell lines, achieving IC50 values of 0.512 µM (ALK), 0.766 µM (ROS1) and 0.034 ± 0.002 µM (H2228). In vitro antitumor assays demonstrated dose-dependent induction of apoptosis in H2228 cells by X4. Western blot (WB) analysis further confirmed that X4 effectively suppresses the expression of p-ALK and p-ERK. Importantly, X4 exhibited high specificity in targeting ALK and ROS1 across a range of kinases. In an H2228 xenograft model, X4 achieved a tumor inhibition rate of 54.71 %, underscoring its considerable potential in ALK/ROS1 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndazolesProtein Kinase InhibitorsAnaplastic Lymphoma KinaseAntineoplastic AgentsProto-Oncogene ProteinsCell ProliferationDose-Response Relationship, DrugProtein-Tyrosine KinasesHumansStructure-Activity RelationshipMolecular StructureAnimalsDrug Screening Assays, AntitumorMiceLung NeoplasmsCell Line, TumorMolecular Docking SimulationApoptosisMice, NudePharmacophore

Stichwörter der Autor:innen

ALKKinase inhibitorsNSCLCROS1

Substanzen

IndazolesProtein Kinase InhibitorsAnaplastic Lymphoma KinaseAntineoplastic AgentsProto-Oncogene ProteinsROS1 protein, humanALK protein, humanProtein-Tyrosine Kinases

Autor:innen und Institutionen

  • Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road, Nanchang, Jiangxi, 330013, China.
  • Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road, Nanchang, Jiangxi, 330013, China. Electronic address: shanxu9891@126…
  • Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road, Nanchang, Jiangxi, 330013, China. Electronic address: wanglinxiao542…
  • Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road, Nanchang, Jiangxi, 330013, China. Electronic address: zhuwufu-1122@1…

Zitieren

APA

Huang, X., Xu, S., An, Y., Lv, X., Tian, L., Xu, S., Wang, L., & Zhu, W. (2025). Revealing 5-(3,5-difluorobenzyl)-1H-indazole as the active pharmacophore of ALK/ROS1 dual inhibitors through theoretical calculations and biological activity evaluations. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.108014

Vancouver

Huang X, Xu S, An Y, Lv X, Tian L, Xu S, et al. Revealing 5-(3,5-difluorobenzyl)-1H-indazole as the active pharmacophore of ALK/ROS1 dual inhibitors through theoretical calculations and biological activity evaluations. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2024.108014

BibTeX
@article{Huang2025,
  author = {Huang, Xiaoling and Xu, Shidi and An, Yufeng and Lv, Xinya and Tian, Lulu and Xu, Shan and Wang, Linxiao and Zhu, Wufu},
  title = {Revealing 5-(3,5-difluorobenzyl)-1H-indazole as the active pharmacophore of ALK/ROS1 dual inhibitors through theoretical calculations and biological activity evaluations},
  journal = {Bioorganic Chemistry},
  year = {2025},
  doi = {10.1016/j.bioorg.2024.108014}
}
Kostenlos starten →